Ascelia Pharma FDA schedules Type A meeting for Orviglance NDA Sep 9, 2026
Ascelia Pharma says the FDA has scheduled a Type A meeting for its Orviglance NDA on September 9, 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.